Overview
- A Nature Communications study analyzed MRI scans from 106 participants in a Phase IIb trial of NG101 after acute cervical spinal cord injury.
- NG101 recipients had faster lesion shrinkage and slower loss of cord size and myelin above the injury than placebo, changes consistent with new fibers reconnecting pathways for hand and arm control.
- NG101 works by neutralizing Nogo-A, a protein that blocks nerve regrowth in the central nervous system.
- Investigators delivered the drug into the spinal canal within weeks of injury and tracked lesion volume, cord cross-sectional area, and myelin integrity over six months.
- The earlier trial did not meet its primary endpoint across all patients, yet MRI picked up structural effects even without clear functional gains, pointing to imaging and electrophysiology to select responders in future studies.